Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Yoshio TakesueHiroki Ikeuchi

Abstract

Recent studies demonstrated that mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia was high when vancomycin was used to treat infections with strains that had a high vancomycin minimum inhibitory concentration (MIC). This study compared several characteristics of vancomycin MIC 2 μg/ml strains isolated from bacteremia with those isolated from infections other than bacteremia. A total of 128 episodes of MRSA bacteremia between 2005 and 2008 were followed-up, and compared with 631 MRSA infections other than bacteremia. The isolation of strains with a 2 μg/ml MIC accounted for 32.0% of isolates from MRSA bacteremia, whereas strains with a 2 μg/ml MIC comprised 9.0% of MRSA isolated from other sites (p < 0.001). The incidence of pneumonia as the source of infection was significantly higher in patients with bacteremia from strains with a 2 μg/ml MIC than in those with ≤1 μg/ml MIC. Prior vancomycin use did not correlate with the isolation of 2 μg/ml strains. The efficacy of glycopeptides as 1st line therapy in patients infected with 2 μg/ml strains was significantly lower than that for patients infected with ≤1 μg/ml strains (30.0 vs. 78.8%, p < 0.001) in bacteremia. In the analysis of infection...Continue Reading

References

Jan 4, 2001·International Journal of Antimicrobial Agents·P A Moise, J J Schentag
Feb 7, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin P HowdenM Lindsay Grayson
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alex SorianoJosep Mensa
May 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George Sakoulas, Robert C Moellering
Jun 17, 2008·The Journal of Antimicrobial Chemotherapy·Juan-Ignacio AlósFrancisco Rodríguez-Salvanés
Oct 1, 2008·Antimicrobial Agents and Chemotherapy·Ilana Lopes Baratella da Cunha CamargoKeiichi Hiramatsu

❮ Previous
Next ❯

Citations

Feb 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S J van HalD L Paterson
May 11, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sheryl A ZelenitskyLavern M Vercaigne
Apr 12, 2012·Clinical Microbiology Reviews·Sebastian J van HalIain B Gosbell
Mar 1, 2012·Therapeutics and Clinical Risk Management·Mao HagiharaHiroshige Mikamo
May 11, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Romney M Humphries, Janet A Hindler
Feb 24, 2015·Journal of Intensive Care·Shigeto OdaUNKNOWN Sepsis Registry Committee of The Japanese Society of Intensive Care Medicine
Jul 30, 2011·International Journal of Antimicrobial Agents·Håkan HanbergerUNKNOWN EPIC II Group of Investigators
May 16, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuaki MatsumotoToshimi Kimura
Dec 24, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sabrina Di GregorioMarta Mollerach
Apr 11, 2017·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yoshio TakesueKatsunori Yanagihara
Dec 22, 2011·The Journal of Antibiotics·Concepción Pérez-JorgeJaime Esteban
Feb 5, 2014·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Motoyasu MiyazakiHidetoshi Kamimura
Jul 9, 2020·Journal of Medical Microbiology·Izumo KanesakaIntetsu Kobayashi
Oct 20, 2020·Brazilian Journal of Microbiology : [publication of the Brazilian Society for Microbiology]·Adriana Medianeira RossatoPedro Alves d'Azevedo
Apr 3, 2021·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Takashi UedaHideki Kawamura
Apr 7, 2011·Thérapie·Mohamed Larbi JelassiUNKNOWN Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.